Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients.

× No keyword cloud information.

8 in total

1. Controlling the Evolution of Resistance.

Authors: Rutao Luo; Lamont Cannon; Jason Hernandez; Michael J Piovoso; Ryan Zurakowski
Journal: J Process Control Date: 2011-03-01 Impact factor: 3.666

Review 2. Current issues and future directions of oncolytic adenoviruses.

Authors: Masato Yamamoto; David T Curiel
Journal: Mol Ther Date: 2009-11-24 Impact factor: 11.454

3. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo.

Authors: Janjira Intra; Aliasger K Salem
Journal: J Control Release Date: 2008-04-24 Impact factor: 9.776

4. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

Authors: Kenneth H Kim; Igor P Dmitriev; Souheil Saddekni; Elena A Kashentseva; Raymond D Harris; Rosemarie Aurigemma; Sejong Bae; Karan P Singh; Gene P Siegal; David T Curiel; Ronald D Alvarez
Journal: Gynecol Oncol Date: 2013-06-10 Impact factor: 5.482

5. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism.

Authors: I Dmitriev; V Krasnykh; C R Miller; M Wang; E Kashentseva; G Mikheeva; N Belousova; D T Curiel
Journal: J Virol Date: 1998-12 Impact factor: 5.103

A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients.

1. Controlling the Evolution of Resistance.

Review 2. Current issues and future directions of oncolytic adenoviruses.

3. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo.

4. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

5. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism.

Review 6. Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements.

7. Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery.

Review 8. Oncolytic viruses: a new class of immunotherapy drugs.